today announced that it will present positive data from its herpes simplex virus-1 keratitis program, EBT-104, as well as an overview of a next-generation AAV delivery vector, at the American ...

Excision’s EBT-104 is a CRISPR-based gene therapy ... observed significant levels of AAV vector genomes in the trigeminal ganglia (TG) where the latent HSV-1 resides. Additionally, we detected ...

Similarly, in another study, a single HSV-1-targeting CRISPR was injected ... The studies suggest that topical application of AAV-expressing CRISPR/Cas9 editing machinery can effectively prevent ...

Infectious disease researchers have used a gene editing approach to remove latent herpes simplex virus ... CRISPR/Cas9. - Refining the vector delivery mechanism, they found the adeno-associated ...

Infections caused by herpes simplex virus type 1 (HSV-1) can lead to HSV-1 encephalitis—a rare but deadly condition that inflames the brain. Despite decades of research, treatment options for this ...

EBT-104 is a CRISPR-based gene therapy designed to potentially eliminate HSV-1 keratitis by inactivating latent HSV-1 in the latent HSV-1 reservoirs. The candidate utilizes a multiplexed CRISPR ...

A key viral mechanism that allows HSV-1 to evade the brain’s natural defenses has been uncovered and tested to identify new ...

Infections caused by herpes simplex virus type 1 (HSV-1) can lead to HSV-1 encephalitis-a rare but deadly condition that inflames the brain.

RNA gene scissors (CRISPR-Cas13) are gaining significant attention as a next-generation gene therapy with fewer side effects.

Researchers from Excision Biotherapeutics Inc. and affiliated organizations have reported the development of a novel CRISPR/Cas9-mediated genome editing therapy – EBT-104 – for the treatment of latent ...